🔗 Share this article America and Britain Finalize Duty-Free Arrangement on Drugs. Conceptual image of drug trade. Britain and America have established a major bilateral deal that will ensure zero import taxes on UK medicine products being sold in the US market. The Terms of the Deal In exchange for the tariff guarantee, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This commitment secures that duties on these vital products will remain at nothing for a period of three years. This deal comes after earlier warnings to hike import taxes on branded pharmaceutical imports, with potential rates mentioned up to one hundred percent. "This deal with the United Kingdom strengthens the global environment for innovative medicines and introduces much-needed balance to American-British drug exports," a statement said. Economic Impact Medicines are one of the UK's biggest goods shipped to the US, which is clearly the primary buyer for major British pharmaceutical firms. Trade data show that in the one-year period prior to the third quarter, the UK exported medicines totaling over eleven billion pounds to the US. This figure made up 17.4% of total UK exports in that period. "This guarantee secures employment, stimulates investment and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented. Specific NHS Changes The agreement involves several key changes from the United Kingdom: Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be unaffordable by a quarter. Higher Drug Budget: There is a aim to increase total health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years. Payback Limit: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be capped at 15%. Last year, repayments were more than 20%. Recent Tensions The deal comes amid a protracted dispute between the drug companies and the ministers over spending levels and regulatory access. These tensions were exacerbated by assertions that US consumers were charged significantly more for the identical medicines than patients in the Britain and the EU. Recently, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been announced toward US facilities. One official publicly accepted that the NHS must increase expenditure on drugs, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
Conceptual image of drug trade. Britain and America have established a major bilateral deal that will ensure zero import taxes on UK medicine products being sold in the US market. The Terms of the Deal In exchange for the tariff guarantee, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This commitment secures that duties on these vital products will remain at nothing for a period of three years. This deal comes after earlier warnings to hike import taxes on branded pharmaceutical imports, with potential rates mentioned up to one hundred percent. "This deal with the United Kingdom strengthens the global environment for innovative medicines and introduces much-needed balance to American-British drug exports," a statement said. Economic Impact Medicines are one of the UK's biggest goods shipped to the US, which is clearly the primary buyer for major British pharmaceutical firms. Trade data show that in the one-year period prior to the third quarter, the UK exported medicines totaling over eleven billion pounds to the US. This figure made up 17.4% of total UK exports in that period. "This guarantee secures employment, stimulates investment and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented. Specific NHS Changes The agreement involves several key changes from the United Kingdom: Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be unaffordable by a quarter. Higher Drug Budget: There is a aim to increase total health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years. Payback Limit: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be capped at 15%. Last year, repayments were more than 20%. Recent Tensions The deal comes amid a protracted dispute between the drug companies and the ministers over spending levels and regulatory access. These tensions were exacerbated by assertions that US consumers were charged significantly more for the identical medicines than patients in the Britain and the EU. Recently, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been announced toward US facilities. One official publicly accepted that the NHS must increase expenditure on drugs, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.